Cognitive effects of Solifenacin 5mg in subjects 75 years and over.

• Research type

  Research Study

• Full title

  A phase I study to compare the cognitive effect of solifenacin 5mg and oxybutynin 5mg twice-daily after chronic dosing versus placebo in subjects over the age of 75 years with Mild Cognitive Impairment: A double-blind, randomized, single centre study.

• IRAS ID

  27152

• Sponsor organisation

  Astellas Pharma Europe BV

• Eudract number

  2008-005966-29

• ISRCTN Number

  N/A

• Research summary

  N/A

• REC name

  London - Brent Research Ethics Committee

• REC reference

  09/H0717/47

• Date of REC Opinion

  28 Oct 2009

• REC opinion

  Further Information Favourable Opinion